Impact of primary site on survival in patients with nasopharyngeal carcinoma from 2004 to 2015

Tianyi Shen1†, Wenting Cai1†, Tingting Li1, Donghui Yu1, Chengda Ren1 and Jing Yu1,2*

1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China, 2Department of Ophthalmology, The Third People’s Hospital of Bengbu, Bengbu, China

Background: Nasopharynx carcinoma (NPC) is the most common malignant tumor of the nasopharynx. Many studies have shown some factors related with the prognosis of NPC patients. Our study aims to evaluate the differences of prognosis between initial and second primary NPC.

Material and methods: The Surveillance, Epidemiology, and End Results (SEER) program was used to perform the population-based analysis in NPC patients who were newly diagnosed between 2004 and 2015. Kaplan-Meier and Cox regressions were used to evaluate the effects of primary site on the overall survival (OS), as well as the cancer-specific survival (CSS).

Results: Our study included 5,012 NPC patients: 4,474 initial primary NPC patients and 538 second primary NPC patients. Significant differences were observed in sex, age at diagnosis, race, median household income, histological type, American Joint Committee on Cancer (AJCC) stage, N-stage, radiation treatment and chemotherapy between patients with initial and second NPC (P<0.05). Moreover, the patients with second NPC had longer survival months. In addition, radiation and chemotherapy were recommended both in first and second primary NPC patients.

Conclusion: Worse prognosis was observed in patients with second primary NPC compared with those with primary NPC in all subgroups of AJCC stage and age at diagnosis.

KEYWORDS nasopharyngeal neoplasms, SEER program, second primary, initial primary, prognosis

Introduction

Nasopharynx carcinoma (NPC) is the most common malignant tumor of the nasopharynx, and this cancer is especially endemic in southeast Asian and Mediterranean populations (1). Other risk factors also include Epstein-Barr virus (EBV) exposure (2–4), environment (5, 6) and heavy alcohol intake (7, 8). This disease is often initially asymptomatic, and the first symptoms (nasal obstruction, sore throat, headache, epistaxis, and seromucous otitis) are non-specific. NPC is unfortunately commonly diagnosed once it is locally evolved, and greater than 80% of patients present with

Abbreviations
NPC, nasopharynx carcinoma; SEER, surveillance, epidemiology, and end results; OS, overall survival; CSS, cancer-specific survival
lymph node metastases at the time of the diagnosis. Based on the World Health Organization (WHO) histopathological grading system (9), there are three types of NPC including keratinizing squamous cell carcinoma, nonkeratinizing squamous cell carcinoma, and undifferentiated carcinoma.

Diagnosis is based on biopsy of the resected nasopharyngeal mass. Prior to biopsy, careful physical examination and fiberoptic endoscopic examination, evaluation of cranial nerve function, computed tomographic (CT) scan, magnetic resonance imaging (MRI) and EBV titers test should be performed (10). Detailed stage information for NPC is defined by the TNM system (11).

Given the proximity between nasopharyngeal cancer and essential risk organs, such as the brainstem and visual apparatus, treatment is complex (10). Standard treatments for nasopharyngeal cancer patients include radiation therapy, concurrent chemoradiation followed by adjuvant chemotherapy, and surgery. Among these treatments, high-dose radiation therapy with chemotherapy is the primary treatment (12). Some new types of treatment for NPC are currently being tested in clinical trials. For example, monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread (13). For patients with EBV infection, a trial focused on EBV DNA-based individualized treatment is ongoing (14, 15). NPC treatments may cause side effects, such as anemia, appetite loss, alopecia, and lymphedema, which are also commonly reported in other cancer treatments.

According to our literature review, major factors affecting the prognosis of NPC include tumor size, and neck node involvement (16). Other factors potentially associated with the outcome of treatment include age, pregnancy, immunodeficiency, incomplete excision of involved neck nodes, and locoregional relapse, are still under study. The purpose of this article is to assess the prognosis differences between patients of initial and second primary NPC.

Material and methods

Study populations

The Surveillance, Epidemiology, and End Results (SEER) database was applied to extract the NPC patients who were diagnosed range from 2004 to 2015. In the present study, we use SEER+Stat 8.3.5 software (National Cancer Institute, Bethesda, MD) to collect the initial data. We obtained detailed data on patients diagnosed with NPC between 2004 and 2015 from SEER-18. We excluded cases using the following criteria: (a) survival time unknown; (b) initial and primary NPC patients with incomplete data; (c) age at diagnosis under 18 years old; (d) data with unknown AJCC and T/N/M stage.

Study variables

Several clinicopathological characteristics were included in our study. Gender was divided into male and female patients. Race was separated into white, black, and unknown. Patients diagnosed in different age were classified into three groups: younger than 45, between 45 and 65, older than 65. Marital status was divided into married, unmarried, and unknown. We also included metropolitan and nonmetropolitan. Median household income was separated into quartiles, quartile I was <$35,000, quartile II was $35,000–$45,000, quartile III was $45,001–$55,000, and quartile IV was >$55,000, respectively. Histology type included squamous cell carcinoma or others. Other indexes such as AJCC stage, T-stage, N-stage, M-stage were divided according to their grades. We considered overall survival (OS) and cancer-specific survival (CSS) as primary outcomes.

Ethical approval and consent

Human participants involved in this study were all subject to the ethical standards of the institutional research committee, and to the 1964 Helsinki declaration as well as its later amendments or comparable ethical standards. No animal studies were included in present study.

Statistical analysis

All analyses were performed using GraphPad Prism version 6.01and IBM SPSS Statistics version 20, the level of statistical significance was considered as P < 0.05. Patients were followed up until December 2015. OS and CSS served as the primary outcomes. In this study, the relevant factors included gender, race, marital status, urban or rural region, age at diagnosis, histology type, median household income, AJCC as well as TNM stage, and treatment including surgery, radiation and chemotherapy. Data are presented as the mean ± SD. Categorical variables were recorded as counts (percentage). Analysis of variance was used to compare continuous variables with symmetric distributions across primary and second NPC subgroups. The Kaplan–Meier method was used to plot the survival distributions. Chi square tests were used to compare categorical variables between subgroups. Next, we conducted a multivariable Cox proportional hazard analysis to obtain hazard ratios (HR) and 95% CI in accordance with demographic and clinical covariates.

Results and analysis

Patient baseline characteristics

We extracted data on 6,744 patients diagnosed with NPC between 2004 and 2015 from SEER-18. According to the schematic
diagram of Figure 1, 5,012 eligible patients were included. For the primary comparison, the original dataset \((n = 5,012)\) included 4,474 initial NPC patients and 538 second primary NPC patients. Significant differences were observed in gender, age at diagnosis, race, median household income, histology type, AJCC stage, N stage, radiation treatment and chemotherapy between these two groups. The majority of cases in our cohort were 45–64 years of age (51.4%), white (47.4%), married (58.6%), nonmetropolitan (83.1%) and histology type of squamous cell carcinoma (59.5%). Second primary NPC patients had higher ratios in diagnosed age (51.4%), white (47.4%), married (58.6%), nonmetropolitan (83.1%) and histology type of squamous cell carcinoma (59.5%) than initial cases \((Table 1)\).

A cohort of 5,012 patients with first and second primary nasopharyngeal carcinoma was included in the study. Patients who died from any cause were more likely to exhibit the following characteristics: second primary carcinoma (57.6%), males (41.4%), older patients (59.0%), unmarried patients (47.3%), metropolitan (49.5%), lower household income (51.9%), squamous cell carcinoma (43.5%), and higher grade of AJCC and TNM stage. Moreover, patients without treatments, including all types of surgeries, radiation and chemotherapy, were more likely to be deceased. Moreover, when analyzed by CSS, 25.8% of patients died from nasopharyngeal cancer, and the results from OS analysis kept the same \((Table 2)\).

Comparison of OS and CSS between initial primary and second primary NPC patients

Log-rank tests for the OS and cause-specific Kaplan-Meier survival curves \((Figure 1)\) revealed significant differences among the primary sites, AJCC grade and age in diagnosis groups. The OS and CSS of patients with initial NPC were significantly increased compared with patients with second NPC \((62.3\% \text{ vs. } 42.4\%, \ P < 0.001, \ Figure 2A; \ 74.6\% \text{ vs. } 66.1\%, \ P < 0.001, \ Figure 2B, \ respectively)\). As shown in Figures 2C,D, OS and CSS of patients with low AJCC grades were significantly increased compared with patients with a high AJCC grade \((P < 0.001)\). Patients whose age at diagnosis was greater than 65 exhibited significantly lower OS and significantly \((both \ P < 0.001, \ Figures 2E,F)\).

Patients were sub grouped according to AJCC stage and age at diagnosis. As shown in Figures 3A,B, patients diagnosed with AJCC I stage and patients with second NPC exhibited increased overall and cancer-specific mortality, and similar findings were noted for AJCC II to IV stage patients. When analyzed by both OS and CSS, the prognosis of second primary NPC was poorer compared with first primary NPC regardless of AJCC grade. As shown in Figure 4, all subgroups of age at diagnosis exhibited consistent results, and patients with second primary carcinoma were more likely to exhibit increased all-cause mortality. However, no significant differences were between the first and second primary sites when patients were diagnosed between 45 and 65 \((P > 0.05, \ Figure 4D)\) and >65 years \((P > 0.05, \ Figure 4F)\) based on CSS analysis.

Univariate and multivariate analysis of factors associated with all-cause mortality and cancer-specific mortality

We performed univariate and multivariate Cox regression analyses to analyze the prognostic factors \(\text{(Table 3)}\). When analyzed by OS, the HR of second NPC was 1.231, and 95% CI was 1.084 to 1.398 \((P < 0.001)\) compared with patients with initial NPC. Increased risks were associated with all-cause mortality in multivariate analysis. According to the univariate analysis, primary sites of second NPC were factors that affected cancer-specific mortality \((HR = 1.517, \ P < 0.001)\) when referred to CSS. In addition, male \((P < 0.05)\), age over 65 years old at diagnosis \((P < 0.001)\), black race \((P < 0.01)\), and histology type of squamous cell \((P < 0.001)\) were all risk factors that affected not only all-cause mortality, but also cancer-specific mortality. AJCC stage, T stage and M stage were also closely associated with overall as well as cancer-specific mortality \((all \ P < 0.05)\), whereas N stage did not influence cancer-specific mortality \((P > 0.05)\). According to multivariate logistic regression for cancer-specific mortality, AJCC stage IV had the highest mortality among all the stages, and the HR was 4.304, with 95% CI ranging from 2.937 to 6.307 when compared with stage I.
TABLE 1 Demographic and clinical characteristics of NPC patients.

| Characteristic         | Total | Initial NPC  |    | Second NPC  |    | P     |
|------------------------|-------|--------------|----|-------------|----|-------|
|                        | N     | N (Percentage)|    | N           |    |       |
| Total                  | 5,012 | 4,474 (89.3%) |    | 538 (10.7%) |    |       |
| Gender                 |       |              |    |             |    | 0.003 |
| Male                   | 3,493 | 3,148 (70.4%) |    | 345 (64.1%) |    |       |
| Female                 | 1,519 | 1,326 (29.6%) |    | 193 (35.9%) |    |       |
| Race                   |       |              |    |             |    | 0.000 |
| White                  | 2,376 | 2,033 (45.4%) |    | 345 (64.1%) |    |       |
| Black                  | 590   | 524 (11.7%)  |    | 66 (12.3%)  |    |       |
| Unknown                | 2,046 | 1,919 (42.9%) |    | 127 (23.6%) |    |       |
| Age at diagnosis       |       |              |    |             |    | 0.000 |
| <45                    | 1,121 | 1,105 (24.7%) |    | 16 (3.0%)   |    |       |
| 45–64                  | 2,575 | 2,337 (52.2%) |    | 238 (44.2%) |    |       |
| ≥65                    | 1,316 | 1,032 (23.1%) |    | 284 (52.8%) |    |       |
| Marital status         |       |              |    |             |    | 0.582 |
| No                     | 1,817 | 1,619 (36.2%) |    | 198 (36.8%) |    |       |
| Yes                    | 2,939 | 2,631 (58.8%) |    | 308 (57.2%) |    |       |
| Unknown                | 256   | 224 (5.0%)   |    | 32 (5.9%)   |    |       |
| Urban-rural residence  |       |              |    |             |    | 0.062 |
| Metropolitan           | 400   | 346 (7.7%)   |    | 54 (10.0%)  |    |       |
| Nonmetropolitan        | 4,612 | 4,128 (92.3%) |    | 484 (90.0%) |    |       |
| Median household income|       |              |    |             |    | 0.001 |
| Quartile I             | 601   | 526 (11.8%)  |    | 75 (13.9%)  |    |       |
| Quartile II            | 1,674 | 1,474 (32.9%) |    | 200 (37.2%) |    |       |
| Quartile III           | 1,209 | 1,068 (23.9%) |    | 141 (26.2%) |    |       |
| Quartile IV            | 1,528 | 1,406 (31.4%) |    | 122 (22.7%) |    |       |
| Histology Type         |       |              |    |             |    | 0     |
| Squamous cell carcinoma| 2,981 | 2,599 (58.1%) |    | 382 (71.0%) |    |       |
| Others                 | 2,031 | 1,875 (41.9%) |    | 156 (29.0%) |    |       |
| AJCC stage             |       |              |    |             |    | 0     |
| I                      | 464   | 376 (8.4%)   |    | 88 (16.4%)  |    |       |
| II                     | 1,137 | 1,010 (22.6%) |    | 127 (23.6%) |    |       |
| III                    | 1,484 | 1,334 (29.8%) |    | 150 (27.9%) |    |       |
| IV                     | 1,927 | 1,754 (39.2%) |    | 173 (32.2%) |    |       |
| T stage                |       |              |    |             |    | 0.411 |
| 0                      | 16    | 14 (0.3%)    |    | 2 (0.4%)    |    |       |
| 1                      | 1,584 | 1,396 (31.2%) |    | 188 (34.9%) |    |       |
| 2                      | 1,214 | 1,093 (24.4%) |    | 121 (22.5%) |    |       |
| 3                      | 1,047 | 933 (20.9%)  |    | 114 (21.2%) |    |       |
| 4                      | 1,151 | 1,038 (23.2%) |    | 113 (21.0%) |    |       |
| N stage                |       |              |    |             |    | 0     |
| 0                      | 1,358 | 1,124 (25.1%) |    | 234 (43.5%) |    |       |
| 1                      | 1,642 | 1,481 (33.1%) |    | 161 (29.9%) |    |       |
| 2                      | 1,374 | 1,277 (28.5%) |    | 97 (18.0%)  |    |       |
| 3                      | 638   | 592 (13.2%)  |    | 46 (8.6%)   |    |       |
| M stage                |       |              |    |             |    | 0.726 |
| 0                      | 4,487 | 4,003 (89.5%) |    | 484 (90.0%) |    |       |
| 1                      | 525   | 471 (10.5%)  |    | 54 (10.0%)  |    |       |

(continued)
In the stratified log-rank test, the overall mortality and cancer-specific mortality for age at diagnosis, AJCC stage, and primary site were 493.836, 352.393 and 105.772, respectively, when analyzed for all causes of death. Similar results were noted for the previously described variables. Chi-square of OS and CSS for factors, such as gender and urban-rural residence, revealed less influence compared with the other variables (Supplementary Figure S1).

Comparison of different therapies for initial and second primary NPC

To analyze better therapies for initial and second NPC at different AJCC stages and age at diagnosis, forest plot was performed to clearly observe the comparison. As shown in Figure 5, surgery, radiation and chemotherapy were applied to initial and second primary NPC patients. Among nonsurgical second primary stage I patients, the overall mortality increased significantly (HR = 2.553, 95% CI = 1.491–8.465). Similar results were noted for patients at different ages of diagnosis. Thus, both the initial and second primary patients could benefit from the prompt therapies.

Discussion

In our study, we used SEER data to assess the interaction between TNM stage, AJCC stage, primary site, histology type, marital status, race, age at diagnosis, and survival in patients with NPC. Patients with second primary NPC suffered worse prognosis in comparison with the initial primary NPC group. Our study showed a significant survival benefit for patients younger than 45 years of age as well, regardless of the primary tumor site. As age increased, the prognosis tended to become worse. Moreover, in each age group, the initial NPC subgroup exhibited a better prognosis compared with the second NPC group. A study showed the negative effect of second primary malignancies, including the occurrence of NPC, on the survival rate of 93,891 patients who suffered from head and neck cancer (17). In addition, it is thought-provoking that in other tumors, such as lung and colorectal cancer, the mortality of the second primary cancer was higher than that of the initial (18, 19). These survival patterns are fundamentally consistent with our literature review. The existence of this situation is complex and multifactorial. Chen et al. found that the longer the interval between the second and initial primary cancer, the higher the morbidity and mortality of the second primary cancer occurred in a 25-year study in Taiwan (20). Kong et al. reported that the morbidity of second primary tumors tended to increase after definitive radiation therapy. Older patients with NPC (age ≥ 50 years) may be at increased risk (21). Chemotherapy and radiation therapy as well as some other types of cancer treatment may increase the risk of a second primary cancer. The presence of an initial primary cancer may also indicate some inherited gene mutations or existing exposure to cancer-causing factors, such as alcohol and tobacco, thus, the risk of second primary cancer increases. Overall, advanced age is the most important risk factor for most cancers (22). In addition to increased susceptibility to cancers, aging patients also commonly exhibit other diseases, leading to a weak physical condition that confers fragility when facing extra health problems and poorer long-term survival. A small discrepancy was noted in the groups of patients >45 years of age. Specifically, differences in CSS rates between initial and second primary NPC were not marked. This finding

| Characteristic | Total | Initial NPC N (Percentage) | Second NPC N (Percentage) | P       |
|---------------|-------|----------------------------|---------------------------|---------|
| Surgery       |       |                            |                           |         |
| Performed     | 4,442 | 496 (11.1%)                | 74 (13.8%)                | 0.065   |
| None or refused | 570 | 3,978 (88.9%)              | 464 (86.2%)               |         |
| Radiation     |       |                            |                           |         |
| Yes           | 1,323 | 1,217 (27.2%)              | 106 (19.7%)               | 0       |
| No            | 3,689 | 3,257 (72.8%)              | 432 (80.3%)               |         |
| Chemotherapy  |       |                            |                           |         |
| Yes           | 3,951 | 3,611 (80.7%)              | 340 (63.2%)               | 0       |
| No            | 1,061 | 863 (19.3%)                | 198 (36.8%)               |         |

NPC, nasopharyngeal carcinoma.
TABLE 2: Univariate analysis of all-cause and NPC-specific mortality for NPC patients.

| Characteristic             | All-cause mortality | NPC-specific death | P  |  |  |
|----------------------------|---------------------|--------------------|----|---|---|
|                            | Dead N (percentage) | Alive N (percentage) | P  | Dead N (percentage) | Alive N (percentage) | P  |
| Total                      | 1,998 (39.9%)       | 3,014 (60.1%)      | 0.000 | 1,046 (25.8%)       | 3,014 (74.2%)       | 0.001 |
| Primary site               |                     |                    |  |  |  |
| Initial NPC                | 1,688 (37.7%)       | 2,786 (62.3%)      | 0.000 | 947 (25.4%)         | 2,786 (74.6%)       | 0.001 |
| Second NPC                 | 310 (57.6%)         | 228 (42.4%)        | 0.001 | 117 (33.9%)         | 228 (66.1%)         | 0.004 |
| Gender                     |                     |                    |  |  |  |
| Male                       | 1,447 (41.4%)       | 2,046 (58.6%)      | 0.000 | 773 (27.4%)         | 2,046 (72.6%)       | 0.000 |
| Female                     | 551 (36.3%)         | 968 (63.7%)        | 0.000 | 291 (23.1%)         | 968 (76.9%)         | 0.000 |
| Age at diagnosis           |                     |                    |  |  |  |
| <45                        | 263 (23.5%)         | 858 (76.5%)        | 0.000 | 171 (16.6%)         | 858 (83.4%)         | 0.000 |
| 45–64                      | 958 (37.2%)         | 1,617 (62.8%)      | 0.000 | 543 (25.1%)         | 1,617 (74.9%)       | 0.000 |
| ≥65                        | 777 (59.0%)         | 539 (41.0%)        | 0.000 | 350 (39.4%)         | 539 (60.6%)         | 0.000 |
| Race                       |                     |                    |  |  |  |
| White                      | 1,100 (46.3%)       | 1,276 (53.7%)      | 0.000 | 521 (29.0%)         | 1,276 (71.0%)       | 0.000 |
| Black                      | 272 (46.1%)         | 318 (53.9%)        | 0.000 | 125 (28.2%)         | 318 (71.8%)         | 0.000 |
| Unknown                    | 626 (30.6%)         | 1,420 (69.4%)      | 0.000 | 418 (22.7%)         | 1,420 (77.3%)       | 0.000 |
| Marital status             |                     |                    |  |  |  |
| No                         | 859 (47.3%)         | 958 (52.7%)        | 0.000 | 429 (30.9%)         | 958 (69.1%)         | 0.000 |
| Yes                        | 1,043 (35.5%)       | 1,896 (64.5%)      | 0.000 | 585 (23.6%)         | 1,896 (76.9%)       | 0.000 |
| Unknown                    | 96 (37.5%)          | 160 (62.5%)        | 0.000 | 50 (23.8%)          | 160 (76.2%)         | 0.000 |
| Urban-rural residence      |                     |                    |  |  |  |
| Metropolitan               | 198 (49.5%)         | 202 (50.5%)        | 0.000 | 88 (30.3%)          | 202 (69.7%)         | 0.052 |
| Nonmetropolitan            | 1,800 (39%)         | 2,812 (61.0%)      | 0.000 | 976 (25.8%)         | 2,812 (74.2%)       | 0.000 |
| Median household income    |                     |                    |  |  |  |
| Quartile I                 | 312 (51.9%)         | 289 (48.1%)        | 0.000 | 144 (33.3%)         | 289 (66.7%)         | 0.000 |
| Quartile II                | 694 (41.5%)         | 980 (58.5%)        | 0.000 | 358 (26.8%)         | 980 (73.2%)         | 0.000 |
| Quartile III               | 500 (41.4%)         | 709 (58.6%)        | 0.000 | 273 (27.8%)         | 709 (72.2%)         | 0.000 |
| Quartile IV                | 492 (32.2%)         | 1,036 (67.8%)      | 0.000 | 289 (21.8%)         | 1,036 (78.2%)       | 0.000 |
| Histology Type             |                     |                    |  |  |  |
| Squamous cell carcinoma    | 1,297 (43.5%)       | 1,684 (56.5%)      | 0.000 | 679 (28.7%)         | 1,684 (71.3%)       | 0.000 |
| Others                     | 701 (34.5%)         | 1,330 (65.5%)      | 0.000 | 385 (22.4%)         | 1,330 (77.6%)       | 0.000 |
| AJCC stage                 |                     |                    |  |  |  |
| I                          | 126 (27.2%)         | 338 (72.8%)        | 0.000 | 42 (11.1%)          | 338 (88.9%)         | 0.000 |
| II                         | 328 (28.8%)         | 809 (71.2%)        | 0.000 | 147 (15.4%)         | 809 (84.6%)         | 0.000 |
| III                        | 541 (36.5%)         | 943 (63.5%)        | 0.000 | 293 (23.7%)         | 943 (76.3%)         | 0.000 |
| IV                         | 1,003 (52.0%)       | 924 (48.0%)        | 0.000 | 582 (38.6%)         | 924 (61.4%)         | 0.000 |
| T stage                    |                     |                    |  |  |  |
| 0                          | 10 (62.5%)          | 6 (37.5%)          | 0.000 | 3 (33.3%)           | 6 (66.7%)           | 0.000 |
| 1                          | 475 (30.0%)         | 1,109 (70.0%)      | 0.000 | 242 (17.9%)         | 1,109 (81.1%)       | 0.000 |
| 2                          | 433 (35.7%)         | 781 (64.3%)        | 0.000 | 217 (21.7%)         | 781 (78.3%)         | 0.000 |
| 3                          | 497 (47.5%)         | 550 (52.5%)        | 0.000 | 273 (33.2%)         | 550 (66.8%)         | 0.000 |
| 4                          | 583 (50.7%)         | 568 (49.3%)        | 0.000 | 329 (36.7%)         | 568 (63.3%)         | 0.000 |
| N stage                    |                     |                    |  |  |  |
| 0                          | 581 (42.8%)         | 777 (57.2%)        | 0.000 | 262 (25.2%)         | 777 (74.8%)         | 0.000 |
| 1                          | 593 (36.1%)         | 1,049 (63.9%)      | 0.000 | 319 (23.3%)         | 1,049 (76.7%)       | 0.000 |
| 2                          | 518 (37.7%)         | 856 (62.3%)        | 0.000 | 297 (25.8%)         | 856 (74.2%)         | 0.000 |
| 3                          | 306 (48.0%)         | 332 (52.0%)        | 0.000 | 186 (35.9%)         | 332 (64.1%)         | 0.000 |

(continued)
may be attributed to the fact that as patients age, more patients die as a result of factors other than NPC, especially in consideration of the aforementioned physical characteristics of aging people.

Female was observed as a weak protective factor for NPC via multivariate analysis. Compared with cases with unknown race information, a notable survival benefit was observed in African and Caucasian patients. Similar results were found both in our study and a previous study, which indicated that survival of initial NPC exhibited no preference for any gender or race (23). However, the concentration on race- or gender-related survival benefits of previous research in second NPC is lacking. NPCs most commonly start in the squamous cells lining the nasopharynx (24). The squamous cell subtype of NPC, which was reported as the major type in both initial and second primary NPC cases, was associated with a less favorable prognosis in our study. Baxi SS et al. reported that many survivors afflicted with head and neck squamous cell carcinomas ultimately died from cancers other than these malignancies and/or noncancer causes (25). The primary site may not significantly affect the prognosis of squamous cell NPCs.

The risk of death was steadily augmented based on elevated tumor T-stage except for T0, and the lethal risk of M1 stage cases dramatically exceeded that of M0. In contrast, such a clear trend was not noted in patients of different N-stage subgroups. Risk of N3 stage noticeably outweighed N0, N1, and N2, but the risks in the three latter stages were not distinguishable. Primary NPC is known for its high metastatic potential, primarily to lymph nodes, via TGF-β/SMAD signaling and Snail/TEL2 pathways (26, 27). Malignancy of tumors exclusively involving adjacent lymph nodes may not conspicuously influence the differences in NPC prognosis. Initial NPC exhibited an incidence roughly equivalent to that of second NPC for each grade of T, N, or M stage. With respect to the composition of T0 group in our dataset (only 16 cases in total and 9 out of them were M1, which meant grouping by one dimension perhaps interrelated with others) and based on clinical experience, we analyzed the AJCC stage of cases. As the stage changed from I to IV, the risk of death significantly increased, ideally displaying the consistency between clinic prognosis and AJCC staging. In each AJCC stage group, the initial NPC subgroup exhibited a more favorable prognosis compared with the second NPC subgroup, indicating that primary site may be an independent risk factor beyond AJCC staging, and second primary malignancies might be a complex condition for current staging systems.

Prominent benefits were also noted for patients receiving standardized treatments compared with untreated. Any type of surgery, radiation, or chemotherapy that was appropriately performed significantly reduced mortality regardless of the primary site. Given that radiation therapy in localized head and neck cancers decreased the incidence of second head and neck cancer cancers, the reason for the better prognosis may be complicated (28). This finding indicates that once NPC is diagnosed, the patient should initiate available treatments as recommended as soon as possible.

The survival trends in SEER datasets in this study are generally consistent with the published literature, and statistical analysis of different aspects revealed compatible results. These results demonstrated that our findings were robust. Although SEER has collected information for cancer

### Table 2 Continued

| Characteristic     | All-cause mortality | NPC-specific death |
|-------------------|---------------------|--------------------|
|                   | Dead N (percentage) | Alive N (percentage) | P | Dead N (percentage) | Alive N (percentage) | P |
| M stage           |                     |                    | 0.000 | 0.000            |
| 0                 | 1,621 (36.1%)       | 2,866 (63.9%)      |     | 826 (22.4%)       | 2,866 (77.6%)       |     |
| 1                 | 377 (71.8%)         | 148 (28.2%)        |     | 228 (61.7%)       | 148 (38.3%)         |     |
| Surgery           |                     |                    | 0.000 | 0.000            |
| Performed         | 177 (31.1%)         | 393 (68.9%)        |     | 79 (16.7%)        | 393 (83.3%)         |     |
| None or refused   | 1,821 (41.0%)       | 2,621 (59.0%)      |     | 985 (27.3%)       | 2,621 (72.7%)       |     |
| Radiation         |                     |                    | 0.000 | 0.000            |
| Yes               | 425 (32.1%)         | 898 (67.9%)        |     | 238 (21.0%)       | 898 (79.0%)         |     |
| No                | 1,573 (42.6%)       | 2,116 (57.4%)      |     | 826 (28.1%)       | 2,116 (70.2%)       |     |
| Chemotherapy      |                     |                    | 0.000 | 0.000            |
| Yes               | 1,441 (36.5%)       | 2,510 (63.5%)      |     | 820 (24.6%)       | 2,510 (75.4%)       |     |
| No                | 557 (52.5%)         | 504 (47.5%)        |     | 244 (32.6%)       | 504 (67.4%)         |     |

NPC, nasopharyngeal carcinoma.
NPC is still a rare tumor in this database considering the significant difference in prevalence among races and districts. Given that certain information is limited in SEER datasets, grouping criteria may not be definite and may require more deliberated discussion. For example, subgroups of the histological type “non-squamous cell carcinoma” and age could be stratified using a more detailed method, which may help adjust the accuracy of our conclusions. Additionally, the factor of interval between the
Survival curves for patients subgrouped by AJCC stage, including stage I (A,B), stage II (C,D), stage III (E,F), and stage IV (G,H).
index cancer and the second primary cancer was not included in this study. Patients with metachronous second primary head and neck cancers exhibit a better prognosis compared with those who present with synchronous lesions, implying the possibility of survival variance between early and late second NPCs (29–31). Tobacco and alcohol use in NPC survivors was not discussed here but has been highlighted as a threat to survival rates of cancer patients (32–34). Given these limitations, future studies are warranted to confirm the observations reported here.
| Overall mortality | Cancer-specific mortality |
|-------------------|--------------------------|
| **Univariate Analysis** | **Multivariate Analysis** | **Univariate Analysis** | **Multivariate Analysis** |
| **HR (95% CI)** | **P** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** |
| Primary site | | | | | | | | |
| Initial NPC | 1 | 0 | 1 | 0.001 | 0 | 0.816 | 1 | 0 |
| Second NPC | 1.863 (1.650–2.103) | 1.231 (1.084–1.398) | 1.517 (1.252–1.838) | NA |
| Gender | 0.002 | 0.002 | 0.006 | 0.023 |
| Male | 1 | 1 | 1 | 1 |
| Female | 0.853 (0.773–0.941) | 0.854 (0.773–0.943) | 0.828 (0.724–0.947) | 0.854 (0.745–0.978) |
| Age at diagnosis | | | | | | | | |
| <45 | 0 | 0 | 0 | 0 |
| 45–64 | 1.808 (1.577–2.073) | 1.667 (1.450–1.915) | 1.683 (1.417–1.999) | 1.653 (1.388–1.967) |
| ≥65 | 3.891 (3.381–4.477) | 3.339 (2.881–3.871) | 3.477 (2.894–4.177) | 3.373 (2.793–4.073) |
| Race | | | | | | | | |
| White | 1 | 1 | 1 | 1 |
| Black | 1.031 (0.903–1.178) | 1.056 (0.923–1.209) | 1.001 (0.824–1.217) | 1.054 (0.865–1.285) |
| Unknown | 0.581 (0.527–0.641) | 0.670 (0.605–0.742) | 0.733 (0.645–0.834) | 0.806 (0.705–0.920) |
| AJCC stage | | | | | | | | |
| II | 1 | 1 | 1 | 1 |
| III | 1.547 (1.274–1.878) | 2.098 (1.614–2.727) | 2.438 (1.764–3.369) | 3.231 (2.230–4.683) |
| IV | 2.830 (2.350–3.408) | 2.425 (1.827–3.219) | 4.929 (3.602–6.744) | 4.304 (2.937–6.307) |
| Histology Type | | | | | | | | |
| Squamous cell carcinoma | 0 | 0 | 0 | 0 |
| Others | 0.691 (0.631–0.758) | 0.806 (0.733–0.886) | 0.695 (0.613–0.787) | 0.792 (0.696–0.900) |
| T stage | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 |
| 1 | 0.387 (0.207–0.724) | 0.920 (0.484–1.750) | 0.615 (0.197–1.920) | 1.938 (0.612–6.136) |
| 2 | 0.484 (0.258–0.906) | 1.051 (0.554–1.997) | 0.766 (0.245–2.392) | 2.142 (0.677–6.778) |
| 3 | 0.760 (0.406–1.421) | 1.404 (0.740–2.665) | 1.349 (0.432–4.208) | 3.041 (0.961–9.619) |
| 4 | 0.918 (0.491–1.716) | 1.580 (0.833–2.995) | 1.684 (0.540–5.249) | 3.182 (1.011–10.820) |
| N stage | | | | | | | | |
| 0 | 0 | 0 | 0 | 0.051 |
| 1 | 0.805 (0.718–0.902) | 0.979 (0.858–1.117) | 0.907 (0.771–1.068) | NA |
| 2 | 0.865 (0.768–0.974) | 0.956 (0.826–1.107) | 1.023 (0.867–1.208) | NA |
| 3 | 1.302 (1.133–1.495) | 1.264 (1.055–1.515) | 1.639 (1.358–1.979) | NA |
| M stage | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 |
| 1 | 3.206 (2.682–3.591) | 2.576 (2.219–2.991) | 4.244 (3.668–4.910) | 2.874 (2.384–3.465) |
| Surgery | | | | | | | | |
| Performed | 0 | 0 | 0 | 0 |
| None or refused | 1.522 (1.304–1.776) | 1.499 (1.248–1.799) | 1.846 (1.468–2.322) | 1.780 (1.405–2.255) |
| Radiation | | | | | | | | |
| Yes | 1 | 1 | 1 | 1 |
| No | 1.502 (1.350–1.672) | 1.138 (1.002–1.292) | 1.477 (1.279–1.706) | NA |
| Chemotherapy | | | | | | | | |
| Yes | 1 | 1 | 1 | 1 |
| No | 1.845 (1.673–2.035) | 2.331 (2.088–2.602) | 1.538 (1.333–1.775) | 2.394 (2.053–2.793) |
Conclusion

In conclusion, our study indicated that patients with second primary NPC exhibited a worse prognosis compared with those with initial NPC in all AJCC stage and age at diagnosis subgroups. Despite the primary site, NPC patients could benefit from standardized treatments, including surgery, radiation and chemotherapy.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by the National Natural Science Foundation of China in 2014 (project number: 81470648) and was also supported by the Fundamental Research Funds for the Central Universities (project number: 22120180509). The authors declare no conflicts of interest.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their...
affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.1001849/full#supplementary-material.

References

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiation versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. (1998) 16:3160–7. doi: 10.1200/JCO.1998.16.12.3160.10
2. Chien YC, Chen JY, Lu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. (2001) 345:1877–82. doi: 10.1056/NEJM011610.10
3. Liang SB, Zhang N, Chen DM, Yang XL, Chen BH, Zhao H, et al. Prognostic value of gross tumor regression and plasma Epstein-Barr virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol. (2013) 132:223–9. doi: 10.1016/j.radonc.2018.10.010.10
4. Lee VH, Kwong DL, Leung TW, Choi CW, O’Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer. (2019) 144:1713–22. doi: 10.1002/ijc.31856.10
5. Fan HC, Chen CY, Hsu YC, Chou RH, Tsang CY, Chiu CH, et al. Increased risk of incident nasopharyngeal cancer with exposure to air pollution. PLoS One. (2018) 13:e0204568. doi: 10.1371/journal.pone.0204568.10
6. Golden R. Identifying an indoor air exposure limit for formaldehyde considering both irritation and cancer hazards. Crit Rev Toxicol. (2011) 41:672–721. doi: 10.3109/10408444.2011.573467.10
7. Shen et al. Carcinoma of the nasopharynx treated by radiotherapy alone: a 10-year study. J Laryngol Otol. (1979) 93:721. doi: 10.3109/10408444.2011.573467.10
8. Lee DJ, Lee HM, Kim JH, Park IS, Rho YS. Heavy alcohol drinking downregulates ALDH2 gene expression but heavy smoking up-regulates SOD2 gene expression in head and neck squamous cell carcinoma. World J Surg Oncol. (2017) 15:163. doi: 10.1186/s12957-017-1225-1.10
9. Lee DJ, Lee HM, Kim JH, Park IS, Rho YS. Heavy alcohol drinking downregulates ALDH2 gene expression but heavy smoking up-regulates SOD2 gene expression in head and neck squamous cell carcinoma. World J Surg Oncol. (2017) 15:163. doi: 10.1186/s12957-017-1225-1.10
10. Lertbutsayanukul C, Kannarunimit D, Netsawang B, Kitpanit S, Chakkabat S, Tait eyes CL, et al. The incidence of incident nasopharyngeal carcinoma with exposure to air pollution. Int J Cancer. (2018) 147:2407–15. doi: 10.1002/ijc.31856.10
11. Compton CC, Byrd DR, Garcia-Aguila J, Kurtzman SH, Olawaiye A, Sullivan J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. (2006) 64:47–56. Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. (2015) 49:907–37. doi: 10.1177/1060022815586218.10
12. Pons 8. doi: 10.1097/MLG.0b013e318172ef9a.10
13. Webber K, Davies AN. An observational study to determine the prevalence of alcohol use disorders in advanced cancer patients. Palliat Med. (2012) 26:360–7. doi: 10.1177/0269216312454674.10
14. Dequanter D, Shahla M, Lardinois I, Gilbert O, Hanquet O, Tragas G, et al. The risk of second primary cancers in patients with nasopharyngeal carcinoma partly by down-regulating TEL2. Int J Radiat Oncol Biol Phys. (2018) 102:1013–25. doi: 10.1016/j.ijrobp.2018.08.006.10
15. Liao LJ, Chou HW, Wang CT, Chung CS, Lai MS. The impact of second primary malignancies on head and neck cancer survivors: a nationwide cohort study. PLoS One. (2013) 8:e62116. doi: 10.1371/journal.pone.0062116.10
16. Yang L, Xiong Z, Xie QK, He W, Liu S, Kong P, et al. Second primary colorectal cancer after the initial primary colorectal cancer. BMC Cancer. (2018) 18:931. doi: 10.1186/s12885-018-4823-6.10
17. Choi E, Luo SJ, Arredou JV, Bachkus LM, Willsden LR, Su CC, et al. The survival impact of second primary lung cancer in patients with lung cancer. J Natl Cancer Inst. (2022) 114:618–25. doi: 10.1093/jnci/djab224.10
18. Chen MC, Feng JJ, Lu CH, Chen CC, Lin JT, Huang SH, et al. The incidence and risk of secondary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979–2003). Ann Oncol. (2008) 19:11880–6. doi: 10.1093/annonc/mdn003.10
19. Kong L, Li J, Hu C, Guo X, Wu Y, Zhang Y. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy: Cancer. (2006) 107:1287–93. doi: 10.1002/ijc.22219.10
20. Chuang SC, Scolo G, Tonita JM, Tamaro S, Jonasson JG, Khewer EY, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer. (2008) 123:2390–6. doi: 10.1002/ijc.23798.10
21. Rose BS, Jeong HJ, Nath SK, Lu SM, Mell IK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. (2011) 29:3503–9. doi: 10.1200/JCO.2011.37.7301.10
22. Yan K, Agrawal N, Gooi Z, Head and neck masses. Med Clin North Am. (2018) 102:1013–25. doi: 10.1016/j.mcna.10
23. Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oefinger CK, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. (2014) 120:1507–13. doi: 10.1002/ijc.23798.10
24. Yan K, Agrawal N, Gooi Z. Head and neck masses. Med Clin North Am. (2018) 102:1013–25. doi: 10.1016/j.mcna.10